Overview

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Status:
Terminated
Trial end date:
2017-05-04
Target enrollment:
Participant gender:
Summary
To determine the safety of extended treatment with Proellex® in women who have successfully completed either study ZPV-201 [NCT02323646] or ZPU-203 [NCT02301897] and meet eligibility criteria.
Phase:
Phase 2
Details
Lead Sponsor:
Repros Therapeutics Inc.